News & insights

Mostafa Kamal, CEO of Prime, told Fierce Healthcare in an interview that patients don't necessarily experience a complex condition through the lens of separate medical and pharmacy benefits, so their care experience should reflect that.

Patrick Gleason, Pharm.D., of Prime Therapeutics was named a 2026 PBMI Innovator for his work on cost-effective formulary strategy and real-world evidence generation.

Mostafa Kamal, chief executive officer at Prime Therapeutics, shares why the key question in the drug pricing debate is not just where health care value is created, but whether it ultimately reaches the patients, employers and health plans paying for care.

Zach Jones, Pharm.D., is senior director of clinical formulary strategy, Prime Therapeutics, a Minnesota-based pharmacy benefit manager.

AMCP 2026 spotlighted oncology innovation, AI, and payer strategies, with KOL insights on cost, access, and evolving managed care trends.

Brian MacDonald, PharmD, and Soumya Vishwanath, PharmD, of Prime Therapeutics shared practical insights on the patient, provider and payer challenges shaping gene therapy adoption at AMCP 2026